Antecedentes Esta la segunda actualización de una revisión publicada anteriormente en la
Biblioteca Cochrane (2015, primera actualización en 2017). La interleucina 5 (IL‐5) es la …

Over the past 20 years, the Global Initiative for Asthma (GINA) has regularly published and
annually updated a global strategy for asthma management and prevention that has formed …

Abstract The ongoing Coronavirus Disease 2019 (COVID-19) pandemic has affected more
than 100 million people and clinics are being established for diagnosing and treating …

Background As asthma symptoms worsen, patients typically rely on short-acting β2-agonist
(SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves …

Background In some patients with moderate-to-severe asthma, particularly those with
noneosinophilic inflammation, the disease remains uncontrolled. This trial evaluated the …

Background Benralizumab is an IL5-receptor monoclonal antibody licensed for the treatment
of severe eosinophilic asthma (SEA). It has demonstrated efficacy in clinical trials in …

Background Eosinophilic granulomatosis with polyangiitis is an eosinophilic vasculitis.
Mepolizumab, an anti–interleukin-5 monoclonal antibody, reduces blood eosinophil counts …

Background Exacerbations of asthma cause a substantial global illness burden. Adults with
uncontrolled persistent asthma despite maintenance treatment require additional therapy …

Background Clinical characteristics of the international population with severe asthma are
unknown. Intercountry comparisons are hindered by variable data collection within regional …

Introduction Consensus definitions for clinical remission and super-response were recently
established for severe asthma. Benralizumab is an interleukin-5 (IL-5) receptor α-directed …